logo

Eiger Biopharmaceuticals Inc. (EIGR)



Trade EIGR now with
  Date
  Headline
5/17/2018 7:21:11 AM Wedbush Is Cutting Eiger BioPharmaceuticals Inc. (EIGR) FY19 Estimate To -2.78 From -2.42
5/17/2018 7:20:59 AM Wedbush Is Cutting Eiger BioPharmaceuticals Inc. (EIGR) Q4 19 Estimate To -0.73 From -0.64
5/17/2018 7:20:46 AM Wedbush Is Cutting Eiger BioPharmaceuticals Inc. (EIGR) Q3 19 Estimate To -0.71 From -0.62
5/17/2018 7:20:33 AM Wedbush Is Cutting Eiger BioPharmaceuticals Inc. (EIGR) Q2 19 Estimate To -0.68 From -0.59
5/17/2018 7:20:18 AM Wedbush Is Lowering Eiger BioPharmaceuticals Inc. (EIGR) Q1 19 Estimate To -0.66 From -0.57
5/17/2018 7:20:04 AM Wedbush Is Lowering Eiger BioPharmaceuticals Inc. (EIGR) FY18 Estimate To -2.65 From -2.32
5/17/2018 7:19:49 AM Wedbush Is Cutting Eiger BioPharmaceuticals Inc. (EIGR) Q4 18 Estimate To -0.53 From -0.46
5/17/2018 7:19:37 AM Wedbush Is Cutting Eiger BioPharmaceuticals Inc. (EIGR) Q3 18 Estimate To -0.60 From -0.53
5/17/2018 7:19:23 AM Wedbush Is Lowering Eiger BioPharmaceuticals Inc. (EIGR) Q2 18 Estimate To -0.70 From -0.61
5/17/2018 7:18:44 AM Wedbush Reiterates Eiger BioPharmaceuticals Inc. (EIGR) At Outperform With $53 Up From $36 Price Target
5/11/2018 8:08:39 AM Eiger Q1 Net Loss $8.8 Mln Or $0.84/Shr Vs Net Loss $11.2 Mln Or $1.34/Shr Last Year
5/9/2018 1:35:56 PM B. Riley FBR Starts Eiger BioPharmaceuticals Inc. (EIGR) At Buy With $24 Price Target
4/26/2018 10:25:25 AM Wedbush Reiterates Eiger BioPharmaceuticals Inc. (EIGR) At Outperform With $36 Price Target
4/17/2018 10:33:05 AM Eiger Reports Addl Positive Lonafarnib Data From LOWR HDV Program
3/26/2018 8:04:58 AM Eiger:First Patient Dosed In Phase2 PREVENT Study Of Exendin 9-39 In Patients Suffering From Post-Bariatric Hypoglycemia
3/22/2018 8:21:38 AM Wedbush Is Raising Eiger BioPharmaceuticals Inc. (EIGR) FY18 Estimate To -2.32 From -3.42
3/22/2018 8:21:21 AM Wedbush Is Increasing Eiger BioPharmaceuticals Inc. (EIGR) Q4 18 Estimate To -0.46 From -0.84
3/22/2018 8:20:58 AM Wedbush Is Increasing Eiger BioPharmaceuticals Inc. (EIGR) Q3 18 Estimate To -0.53 From -0.85